The usefulness of serum levels of CEA, CA 50, and ferritin in the management of renal cell cancer.
The aim of this study is to show the usefulness of serum CEA, CA 50, and ferritin levels in the treatment of patients with kidney cancer. Serum CEA and ferritin were determined by EIA assay using Hoffman-la Roche (Austria) kits and serum CA 50 by fluorometric assay using Delfia Pharmacia LKB (Sweden) kits. Cut-off values were 3 ng/mL for CEA, 17 U/mL for CA 50, and 180 ng/mL for ferritin. Increases in the serum levels of CA 50 and ferritin were found to herald the postoperative recurrence of kidney cancer.
Kokociñska
D
D
Department of General Surgery, Silesian University Medical School, Sosnowiec, Poland.
Rajchel
K
K
Nalewajka
E
E
Zagalski
K
K
D000328:Adult; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000628:therapy*; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; C082699:CA-50 antigen; D002272:Carcinoembryonic Antigen; D005293:Ferritins